Adipotide is a ligand-directed peptide analog that is capable of mimicking the actions of natural peptides. Adipotide has been shown to reduce body fat through the mechanism of targeted apoptosis of the blood vessels found throughout adipose tissue.

A study conducted by Barnhart et. Al, examined the activity and effectiveness of adipotide in obese rhesus macaques. The monkeys chosen for this study were all adult females ages 9 to 13, and each monkey weighed anywhere from 10.0 kg to 11.7 kg with a BMI ranging from 34 to 45. Additionally, each monkey held the extra weight primarily in the abdominal area.

Adipotide was subcutaneously injected in increasing doses starting at 0.10 mg/kg to 0.75 mg/kg over the course of 9 weeks. With the increasing doses, the study found that adipotide was successful in reducing body weight, the circumference of the abdomen, and BMI. The two initial monkeys that received treatment saw a 1.8 kg and a 2.1 kg drop in body weight, respectively. The BMI of the morbidly obese monkey dropped 17.1% from 45 to 37.3 while the BMI of the other monkey dropped 20.4% from 38.8 to 30.9. The circumference of the abdomen also dropped significantly by 6.5 cm in the first monkey and 9.0 cm in the second monkey.

Additionally, the experiment found the treatment with adipotide led to decreased insulin resistance. The morbidly obese monkeys were confirmed to be insulin-resistant through an intravenous glucose tolerance test. The obese monkeys seemed to have relatively normal insulin responses. Following testing with adipotide, the area under the curve regarding levels of insulin resistance decreased by 61.4% in the morbidly obese monkey and 63.5% in the obese monkey.

Overall the study concluded that the optimal dose for adipotide in rhesus macaques was approximately 0.43 mg/kg. Through the use of DEXA scans and MRIs the researchers were able to confirm that dosing the experimental group of morbidly obese and obese monkeys with adipotide led to an overall decrease in body weight, abdominal circumference, BMI, and insulin resistance. In comparison, the control group of obese monkeys injected with saline did not see a change in any of the measured variables.

It should be noted that throughout the 9 weeks of subcutaneous treatment with adipotide, the monkeys remained alert and did not experience any kind of nausea, vomiting, or aversion to food. Both the experimental group and the control group ate primate biscuits and enrichment supplements, and each meal and the amount of food eaten were documented in order to show that there was no extreme change in appetite when testing with adipotide (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666164/).

Peptides Prefer the Cold

In order to reduce peptide breakdown, keep peptides refrigerated at all times but DO NOT FREEZE.
Swab the top of the vial with a 95% alcohol wipe before accessing.
Only Mix with Sterile Bacteriostatic Water
Bacteriostatic water is vital to preventing contamination and preserving the stability of the compound.
Push the needle through the stopper at an angle in order to direct the stream to the side of the vial.
Reconstituted peptide solution should be stored at around 4 degrees Celsius but not frozen, while lyophilized peptide solution should be kept at -20 degrees Celsius.